Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

02/feb/2018 10:54:35 pbi Contatta l'autore

Attention Deficit Hyperactivity Treatment Disorder

 

Attention deficit hyperactivity disorder is one of the most common brain disorder characterized by impairing and pervasive symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (<12 years age) as compared to adolescents. It is also known as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause of the Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be resulted due to genetic factors and environmental influences. It results in improper functioning of the nervous system that led to attention deficit and hyperactivity/impulsiveness condition. The major symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The treatment includes different modalities such as medication, psychotherapy, and education/training.

 

The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is growing at a significant CAGR due to changing in lifestyle and systems impacting the quality of the births. Increase in the use of preservatives and additives in children’s diet, an increase in the prevalence of attention deficit hyperactivity disorder among children about 4–17 year age group expected to fuel the growth of attention deficit hyperactivity disorder treatment market over the forecast period. Moreover, increase in the adoption rate of diagnostic guidelines, increasing awareness among patients and physicians about attention deficit hyperactivity disorder treatment are expected to bolster the revenue growth of attention deficit hyperactivity disorder treatment therapeutics market over the forecast period. However, the presence of comorbid conditions in children leads to underdiagnoses of attention deficit hyperactivity disorder treatment, lack of availability of non-stimulant drugs, stringent regulatory guidelines, and a high cost of the medication are expected to hamper the growth of attention deficit hyperactivity disorder treatment market over the forecast period.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/#ulp-4H8Z4LpNMLEuOnnx

 

The global attention deficit hyperactivity disorder treatment market is segmented on the basis of medication type, age group, and distribution channel

 

Based on medication type, the attention deficit hyperactivity disorder treatment market has been segmented into following:

  • Stimulants
    • Amphetamines
    • Methylphenidate
    • Dextroamphetamine
    • Dexmethylphenidate
  • Non-Stimulants
    • Atomoxetine
    • Bupropion
    • Guanfacine

 

Based on the age group, the attention deficit hyperactivity disorder treatment market has been segmented into following:

  • Paediatric
  • Adolescent
  • Adults

 

Based on the distribution channel, the attention deficit hyperactivity disorder treatment market has been segmented into following:

  • Hospital pharmacies
  • Specialty clinics
  • Retail pharmacies
  • Online pharmacies

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/#ulp-c654SbFYO64MsOhu

 

Nowadays, the global attention deficit hyperactivity disorder treatment market is in a nascent stage, several local and international players are actively involved in the growth of global attention deficit hyperactivity disorder treatment market. Launching of new products, collaborations, acquisitions and mergers, and agreements are some of the key strategies followed by various companies to increase their attention deficit hyperactivity disorder treatment market share. For instance, in August 2011, MonoSol Rx, was partnered again with KemPharm to develop a second oral film product to treat attention deficit hyperactivity disorder treatment. Similarly, in May 2013, NeuroSigma received Health Canada approval for its Monarch eTNS System for the treatment of majorsdepressive disorder and drug-resistant epilepsy, and attention deficit hyperactivity disorder. Deficiency hyperactivity disorder treatment market. For instance, in September 2010, Actavis receives FDA approval of Atomoxetine HCl Capsules for the treatment of attention deficit hyperactivity disorder. And interest expiries are key factors driving the attention deficit hyperactivity disorder treatment market growth overforecast period.

 

Globally, the attention deficit hyperactivity disorder treatment market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in global attention deficit hyperactivity disorder treatment market followed by Europe and Asia-Pacific. North America holds the largest share of hyperactivity disorder, low threshold of diagnosis is expected to boost the deficit deficit hyperactivity disorder treatment therapeutics market in the North American region over the forecast period. Moreover, increase in healthcare expenditure, ongoing clinical trials, early approval of drugs in the US, favorable insurance policies for brain monitoring technologies, and technological advancement for the treatment could fuel the attention deficit hyperactivity disorder treatment market. Europe, Europe, 2008 Asia-Pacific holds a dominant share in attention deficit hyperactivity disorder treatment market owing to developing healthcare infrastructure, government initiatives, a rise in population, and an increase in the number of mental disorders. Japan is the key region in attention deficits hyperactivity disorder treatment in the prevalence of attention deficit hyperactivity disorder among children which is approximately 7.7%.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/#ulp-14mlyhjMGhVjZqa3

 

Neos Therapeutics, Inc. (US), Pfizer Inc. (US), Supernus Pharmaceuticals, Inc. (US), Shire plc (Ireland), MonoSol Rx (US) ), KemPharm, Inc. (US), Neurosigma, Inc. (US) and Actavis (US) to name a few.

Get access to full summary @

 

https://www.precisionbusinessinsights.com/market-reports/global-attention-deficit-hyperactivity-treatment-disorder-adhd-market/

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl